{
    "id": 25995,
    "fullName": "BTK T316A",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BTK T316A lies within the SH2 domain of the Btk protein (UniProt.org). T316A has been demonstrated to confer resistance to resistance to Imbruvica (ibrutinib) in culture (PMID: 27626698), but has not been biochemically characterized and therefore, its effect on Btk protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 7677,
                    "pubMedId": 27626698,
                    "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626698"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 695,
        "geneSymbol": "BTK",
        "terms": [
            "BTK",
            "AGMX1",
            "AT",
            "ATK",
            "BPK",
            "IGHD3",
            "IMD1",
            "PSCTK1",
            "XLA"
        ]
    },
    "variant": "T316A",
    "createDate": "01/25/2017",
    "updateDate": "10/07/2019",
    "referenceTranscriptCoordinates": {
        "id": 144059,
        "transcript": "NM_000061",
        "gDna": "chrX:g.101358645T>C",
        "cDna": "c.946A>G",
        "protein": "p.T316A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lymphoma cells expressing BTK T316A were resistant to Imbruvica (ibrutinib) in culture (PMID: 27626698)",
            "molecularProfile": {
                "id": 27136,
                "profileName": "BTK T316A"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7677,
                    "pubMedId": 27626698,
                    "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27626698"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27136,
            "profileName": "BTK T316A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144059,
            "transcript": "NM_000061",
            "gDna": "chrX:g.101358645T>C",
            "cDna": "c.946A>G",
            "protein": "p.T316A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 144060,
            "transcript": "NM_001287345",
            "gDna": "chrX:g.101358645T>C",
            "cDna": "c.946A>G",
            "protein": "p.T316A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}